City Therapeutics, Inc. (CTY) fair value analysis
Nasdaq · Updated 2026-10-26
CTY price how computed
Valuation status
No fair-value estimate yetCTY has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for CTY yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $20.77
- Sector
- Healthcare
- Market cap
- $1.05B
- Shares outstanding
- 50.3M
- Rank in Healthcare by quality score
- #183 of 302
Last price is the 2026-10-23 close; the chart runs through 2026-10-23.
City Therapeutics, Inc. is a biopharmaceutical company that develops and commercializes therapies for treating serious diseases, with a focus on innovative drug development and clinical research. The company operates in the United States and conducts its business activities through operations located in major pharmaceutical hubs.
CTY currently ranks #183 of 302 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $1.05B
- Revenue (TTM)
- $6.49B
- Net margin
- 27.7%
- Gross margin
- 6.5%
- Debt / equity
- 0.46
- Revenue growth (3-yr avg)
- -25.2%
- Shares outstanding
- 50.3M
Derived indicators how computed
- Quality grade
- F
- Margin trend
- Contracting
What our data shows for CTY
- CTY is covered in the Nasdaq universe of TickrTrends' weekly Forward Fair Value refresh.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- CTY's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the CTY conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-26 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is CTY stock undervalued?
TickrTrends has no fair-value estimate for CTY yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is CTY's TickrTrends verdict?
CTY is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does CTY compare to other Healthcare stocks?
CTY ranks #183 of 302 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is CTY overbought or oversold?
TickrTrends does not currently publish an RSI signal for CTY.